论文部分内容阅读
用双抗体夹心法（ＥＬＩＳＡ）检测了９６例中晚期胃癌、１７例早期胃癌和１６例胃溃疡患者血清ＬＮ和ｓＩＬ－２Ｒ水平。结果表明：中晚期胃癌患者血清ＬＮ含量明显高于健康对照组和胃溃疡患者，也高于早期胃癌患者，早期胃癌、中晚期胃癌患者血清ｓＩＬ－２Ｒ水平呈进行性增高。以健康人血清ＬＮ和ｓＩＬ－２Ｒ水平上限为界，中晚期胃癌ＬＮ阳性率为８７．５％，中晚期胃癌的ｓＩＬ－２Ｒ阳性率为８８．５％，早期胃癌阳性率分别为２９．４％和５２．９％。提示ＬＮ和ｓＩＬ－２Ｒ血清学检测可作为胃癌辅助诊断和病情监测的参考指标。
The levels of serum LN and sIL-2R in 96 patients with advanced and advanced gastric cancer, 17 patients with early gastric cancer and 16 patients with gastric ulcer were measured by double antibody sandwich (ELISA). The results showed that serum LN levels in patients with advanced gastric cancer were significantly higher than those in healthy controls and gastric ulcer patients, and were also higher than those in early gastric cancer patients. Serum sIL-2R levels in patients with early gastric cancer and advanced gastric cancer were progressively increased. The upper limit of serum LN and sIL-2R levels in healthy people was the upper limit. The positive rate of LN in advanced gastric cancer was 87.5%, the positive rate of sIL-2R was 88.5% in advanced gastric cancer, and the positive rate of early gastric cancer was 29.4. % and 52.9%. It is suggested that serological tests of LN and sIL-2R can be used as reference indicators for the diagnosis and monitoring of gastric cancer.